Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSORA study of probenecid effects on sorafenib pharmacokinetics
2017-002470-40Phase 4Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of probenecid and sorafenib in hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (ccRCC) and well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Sorafenib AUC with probenecid relative to sorafenib alone. Started Aug 2017; status: active.
02
Drugs
probenecidsorafenib
03
Conditions
hepatocellular carcinoma (HCC)clear cell renal cell carcinoma (ccRCC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2017-002470-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002470-40.